Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO 0.63%) were lower by 4% as of 11 a.m. ET today. The move comes as ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

Novo Nordisk river nu en aftale i stykker, som ellers blev underskrevet for mindre end to måneder siden. Sidst i april indgik ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...

Novo’s weight-loss drugs are administered by injection and a pill version would be more convenient for patients, ... Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills.

Ozempic maker Novo Nordisk NOVO.B-0.99%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...

Jørgensen, who joined Novo in 1991 and became CEO in 2017, will stay on for a transition period, the company said.A search for his successor is underway. “Novo Nordisk’s strategy remains ...

Novo Nordisk’s value more than quintupled between 2017 and 2024, but the company’s shares have fallen sharply since late last year, weighed down by Big Pharma rivals catching up and the ...